Skip to content

Alogliptin

Nesina, Vipidia (alogliptin) is a small molecule pharmaceutical. Alogliptin was first approved as Nesina on 2013-01-25. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Oseni's patents are valid until 2029-06-16 (FDA).
Trade Name Vipidia
Common Name Alogliptin
Indication type 2 diabetes mellitus
Drug Class Dipeptidyl aminopeptidase-IV inhibitors
Alogliptin
Get full access now